Anti-Epo receptor antibodies do not predict Epo receptor expression
Top Cited Papers
- 1 March 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (5) , 1892-1895
- https://doi.org/10.1182/blood-2005-10-4066
Abstract
Investigators using anti-EpoR antibodies for immunoblotting and immunostaining have reported erythropoietin receptor (EpoR) expression in nonhematopoietic tissues including human tumors. However, these antibodies detected proteins of 66 to 78 kDa, significantly larger than the predicted molecular weight of EpoR (56-57 kDa). We investigated the specificity of these antibodies and showed that they all detected non-EpoR proteins. C-20 detected 3 proteins in tumor cell lines (35, 66, and 100 kDa). Sequences obtained from preparative gels had similarity to the C-20–immunizing peptide. The 66-kDa protein was a heat shock protein (HSP70) to which antibody binding was abrogated in peptide competition experiments. Antibody M-20 readily identified a 59-kDa EpoR protein. However, neither M-20 nor C-20 was suitable for detection of EpoR using immunohistochemical methods. We concluded that these antibodies have limited utility for detecting EpoR. Thus, reports of EpoR expression in tumor cells using these antibodies should be viewed with caution.Keywords
This publication has 18 references indexed in Scilit:
- Erythropoietin and erythropoietin receptor expression in human prostate cancerLaboratory Investigation, 2005
- Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injuryJournal of Experimental Biology, 2004
- Prognostic significance of erythropoietin expression in human endometrial carcinomaCancer, 2004
- Hypoxia-Inducible Erythropoietin Signaling in Squamous Dysplasia and Squamous Cell Carcinoma of the Uterine Cervix and Its Potential Role in Cervical Carcinogenesis and Tumor ProgressionThe American Journal of Pathology, 2003
- Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinomaCancer, 2002
- Burning up TNF toxicity for cancer therapyNature Medicine, 2002
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000
- Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptorCell, 1995
- Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface.Proceedings of the National Academy of Sciences, 1991
- Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.Proceedings of the National Academy of Sciences, 1983